Protachykinin-1, Protachykinin 1, 4930528L02Rik, NK-1, NK1, Nka, Nkna, Neurokinin 2, Neurokinin A, Neurokinin alpha, Neuromedin L, Neuropeptide K, Substance P, Tachykinin precursor 1.
Protachykinin-1, Protachykinin 1, 4930528L02Rik, NK-1, NK1, Nka, Nkna, Neurokinin 2, Neurokinin A, Neurokinin alpha, Neuromedin L, Neuropeptide K, Substance P, Tachykinin precursor 1.
Tachykinin-1, also known as Substance P, is a member of the tachykinin family of neuropeptides. These peptides are characterized by a common C-terminal sequence, which is essential for their biological activity. Tachykinin-1 plays a crucial role in various physiological processes, including pain transmission, inflammation, and smooth muscle contraction.
Tachykinin-1 is an undecapeptide, meaning it consists of 11 amino acids. The amino acid sequence of Tachykinin-1 is Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 . This sequence is highly conserved across different species, indicating its importance in biological functions.
The synthesis of recombinant Tachykinin-1 involves the use of genetic engineering techniques. The gene encoding Tachykinin-1 is inserted into an expression vector, which is then introduced into a host cell, such as E. coli or yeast. The host cells produce the peptide, which is subsequently purified for research or therapeutic use.
Tachykinin-1 exerts its effects by binding to the neurokinin-1 receptor (NK1R), a G protein-coupled receptor found in both the central and peripheral nervous systems . The binding of Tachykinin-1 to NK1R triggers a cascade of intracellular events, leading to the activation of various signaling pathways. These pathways are involved in the transmission of pain signals, regulation of inflammatory responses, and modulation of smooth muscle activity .
Recombinant Tachykinin-1 has been extensively studied for its potential therapeutic applications. It is used in research to understand the mechanisms underlying pain and inflammation. Additionally, NK1R antagonists, which block the binding of Tachykinin-1 to its receptor, are being developed as potential treatments for conditions such as chronic pain, depression, and chemotherapy-induced nausea and vomiting .